Drug Type Small molecule drug |
Synonyms O-(chloroacetylcarbamoyl)fumagillol, O-chloroacetylcarbamoylfumagillol, AGM 1470 + [2] |
Target |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), Aminopeptidase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H28ClNO6 |
InChIKeyMSHZHSPISPJWHW-PVDLLORBSA-N |
CAS Registry129298-91-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | US | 01 Aug 1999 | |
Breast Cancer | Phase 2 | US | - | - |
Breast Cancer | Phase 2 | - | - | |
Kaposi Sarcoma | Phase 2 | US | - | - |
Kaposi Sarcoma | Phase 2 | - | - | |
Kidney Neoplasms | Phase 2 | US | - | - |
Pancreatic Cancer | Phase 2 | US | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Renal Cell Carcinoma | Phase 2 | - | - | |
Leukemia | Phase 1 | US | - | - |